Recombinant Human VEGFA(aa 27-171) fused with an N-terminal Met was expressed in E. coli.
Predicted N Terminal:
Met-Ala27 & Pro28
Lyophilized from a 0.2 μm filtered solution in HCl with BSA as a carrier protein.
Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1323. The ED50 for this effect is typically 12-60 ng/mL.
Predicted Molecular Mass: 17 (monomer) kDa;SDS-PAGE: 20 kDa, reducing conditions.
<0.10 EU per 1 μg of the protein by the LAL method.
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain
Avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 centigrade as supplied.1 month, 2 to 8 centigrade under sterile conditions after reconstitution.3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
Reconstitute at 100 μg/mL 4 mM HCl containing at least 0.1% human or bovine serum albumin.